CN116829725A - 用于产生腺相关病毒的试剂盒及其利用 - Google Patents

用于产生腺相关病毒的试剂盒及其利用 Download PDF

Info

Publication number
CN116829725A
CN116829725A CN202280013880.9A CN202280013880A CN116829725A CN 116829725 A CN116829725 A CN 116829725A CN 202280013880 A CN202280013880 A CN 202280013880A CN 116829725 A CN116829725 A CN 116829725A
Authority
CN
China
Prior art keywords
gene
adeno
vector
genes
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280013880.9A
Other languages
English (en)
Chinese (zh)
Inventor
森勇介
村口太一
梅谷彩也子
渡边裕也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of CN116829725A publication Critical patent/CN116829725A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280013880.9A 2021-02-12 2022-02-10 用于产生腺相关病毒的试剂盒及其利用 Pending CN116829725A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021020868 2021-02-12
JP2021-020868 2021-02-12
PCT/JP2022/005335 WO2022172986A1 (ja) 2021-02-12 2022-02-10 アデノ随伴ウイルスを産生するためのキットおよびその利用

Publications (1)

Publication Number Publication Date
CN116829725A true CN116829725A (zh) 2023-09-29

Family

ID=82838325

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280013880.9A Pending CN116829725A (zh) 2021-02-12 2022-02-10 用于产生腺相关病毒的试剂盒及其利用

Country Status (5)

Country Link
US (1) US20240018547A1 (https=)
EP (1) EP4293118A4 (https=)
JP (1) JPWO2022172986A1 (https=)
CN (1) CN116829725A (https=)
WO (1) WO2022172986A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4624584A1 (en) * 2022-12-27 2025-10-01 Synplogen Co., Ltd. Helper gene control

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3097399A (en) * 1998-03-20 1999-10-11 Trustees Of The University Of Pennsylvania, The Compositions and methods for helper-free production of recombinant adeno-associated viruses
DE10044384A1 (de) * 2000-09-08 2002-04-18 Medigene Ag Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung
US9441244B2 (en) * 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2005116224A2 (en) * 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
US10858631B2 (en) 2017-04-18 2020-12-08 Glaxosmithkline Intellectual Property Development Limited Methods for adeno-associated viral vector production
EP3456822A1 (en) * 2017-09-19 2019-03-20 CEVEC Pharmaceuticals GmbH Inducible aav rep genes
JP6901689B2 (ja) 2018-09-28 2021-07-14 日亜化学工業株式会社 非水電解質二次電池用正極活物質及びその製造方法
GB201816919D0 (en) * 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
SG11202106217TA (en) * 2018-12-21 2021-07-29 Lonza Walkersville Inc Adeno-associated virus (aav) producer cell line and related methods
WO2020235543A1 (ja) 2019-05-20 2020-11-26 Ｊｃｒファーマ株式会社 組換えａａｖビリオンの製造に用いる核酸分子

Also Published As

Publication number Publication date
JPWO2022172986A1 (https=) 2022-08-18
EP4293118A1 (en) 2023-12-20
EP4293118A4 (en) 2025-01-22
WO2022172986A1 (ja) 2022-08-18
US20240018547A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
JP7561788B2 (ja) 臨床使用に適した無血清懸濁細胞培養システムにおいて組換えアデノ随伴ウイルス（ａａｖ）ベクターを産生するスケーラブルな方法
US20240425826A1 (en) Producer cell, manufacturing method of producer cell, and manufacturing method of adeno-associated virus
JP2024538792A (ja) 無血清浮遊培養に適したｈｅｋ２９３細胞株及びその応用
WO2022038369A1 (en) Method of making recombinant aavs
US20240018547A1 (en) Kit for producing adeno-associated virus, and use thereof
US20240263149A1 (en) Manufacturing method of adeno-associated virus, cell, and expression vector
JP2024523891A (ja) Ａａｖ産生方法
WO2024143440A1 (ja) アデノ随伴ウイルスの製造方法、およびベクターのセット
JP7834758B2 (ja) 低レベルのｖａ－ｒｎａを有する産生細胞
WO2024013239A1 (en) Method for producing recombinant aav particles
CN115087738A (zh) 用于穿越人血脑屏障的腺相关病毒载体
WO2025206262A1 (ja) 変異ＲＥＰタンパク質、ｒｅｐ遺伝子およびその利用
EP4502166A1 (en) Efficient system for producing adeno-associated virus (aav) vector
HK40117756A (zh) 用於生产重组aav颗粒的方法
WO2025159153A1 (ja) ウイルスベクターの製造方法
WO2025168663A1 (en) Method for producing recombinant adeno-associated viral particles
EP4683676A1 (en) Method for the production of recombinant aav particle preparations
JP2025530294A (ja) 完全なａａｖ粒子と空のａａｖ粒子を分離するための方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination